ReviewClinical ophthalmology (Auckland, N.Z.)2015
Recent developments in the management of dry age-related macular degeneration.
Review in Clinical ophthalmology (Auckland, N.Z.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.The Cochrane database of systematic reviews · 2023Pooled it
- Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.The Cochrane database of systematic reviews · 2017Pooled it
- Different Therapeutic Approaches for Dry and Wet AMD.International journal of molecular sciences · 2024Review
- Antioxidants and Mechanistic Insights for Managing Dry Age-Related Macular Degeneration.Antioxidants (Basel, Switzerland) · 2024Review
- Liquid-Driven Microinjection System for Precise Fundus Injection.Sensors (Basel, Switzerland) · 2024Article
- Article
- Enriched environment and visual stimuli protect the retinal pigment epithelium and photoreceptors in a mouse model of non-exudative age-related macular degeneration.Cell death & disease · 2021Article
- The Protective Effects ofAntioxidants (Basel, Switzerland) · 2021Article
- Article
- Effects of Vitamin DFrontiers in pharmacology · 2021Article
- Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Age-Related Macular Degeneration.Medicines (Basel, Switzerland) · 2020Article
- Curcumin as a Therapeutic Option in Retinal Diseases.Antioxidants (Basel, Switzerland) · 2020Review
- Observational
- N-Acetyl-L-cysteine Protects Human Retinal Pigment Epithelial Cells from Oxidative Damage: Implications for Age-Related Macular Degeneration.Oxidative medicine and cellular longevity · 2019Article
- A Solid Dispersion of Quercetin Shows Enhanced Nrf2 Activation and Protective Effects against Oxidative Injury in a Mouse Model of Dry Age-Related Macular Degeneration.Oxidative medicine and cellular longevity · 2019Article
- Genetic screening for macular dystrophies in patients clinically diagnosed with dry age-related macular degeneration.Clinical genetics · 2018Article
- Hsp90 inhibition as a means to inhibit activation of the NLRP3 inflammasome.Scientific reports · 2018Article
- Superior cervical gangliectomy induces non-exudative age-related macular degeneration in mice.Disease models & mechanisms · 2018Article
- Retinal Protection and Distribution of CurcuminFrontiers in pharmacology · 2018Article
- Nitroxides as Antioxidants and Anticancer Drugs.International journal of molecular sciences · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry age-related macular degeneration (AMD), also called geographic atrophy, is characterized by the atrophy of outer retinal layers and retinal pigment epithelium (RPE) cells. Dry AMD accounts for 80% of all intermediate and advanced forms of the disease. Although vision loss is mainly due to the neovascular form (75%), dry AMD remains a challenge for ophthalmologists because of the lack of effective therapies. Actual management consists of lifestyle modification, vitamin supplements, and supportive measures in the advanced stages. The Age-Related Eye Disease Study demonstrated a statistically significant protective effect of dietary supplementation of antioxidants (vitamin C, vitamin E, beta-carotene, zinc, and copper) on dry AMD progression rate. It was also stated that the consumption of omega-3 polyunsaturated fatty acids, such as docosahexaenoic acid and eicosapentaenoic acid, has protective effects. Other antioxidants, vitamins, and minerals (such as crocetin, curcumin, and vitamins B9, B12, and B6) are under evaluation, but the results are still uncertain. New strategies aim to 1) reduce or block drusen formation, 2) reduce or eliminate inflammation, 3) lower the accumulation of toxic by-products from the visual cycle, 4) reduce or eliminate retinal oxidative stress, 5) improve choroidal perfusion, 6) replace/repair or regenerate lost RPE cells and photoreceptors with stem cell therapy, and 7) develop a target gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.